Dooley MA - Search Results

1

Environmental epidemiology and risk factors for autoimmune disease.

Dooley MA, Hogan SL. Dooley MA, et al. Curr Opin Rheumatol. 2003 Mar;15(2):99-103. doi: 10.1097/00002281-200303000-00002. Curr Opin Rheumatol. 2003. PMID: 12598794 Review.

2

Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit.

Satoh M, Ajmani AK, Stojanov L, Langdon JJ, Ogasawara T, Wang J, Dooley MA, Richards HB, Winfield JB, Carter TH, Reeves WH. Satoh M, et al. Among authors: dooley ma. Clin Exp Immunol. 1996 Sep;105(3):460-7. doi: 10.1046/j.1365-2249.1996.d01-775.x. Clin Exp Immunol. 1996. PMID: 8809135 Free PMC article.

3

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.

Dooley MA, Hogan S, Jennette C, Falk R. Dooley MA, et al. Kidney Int. 1997 Apr;51(4):1188-95. doi: 10.1038/ki.1997.162. Kidney Int. 1997. PMID: 9083285

4

Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson GS. Cooper GS, et al. Among authors: dooley ma. Arthritis Rheum. 1998 Oct;41(10):1714-24. doi: 10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U. Arthritis Rheum. 1998. PMID: 9778212 Review. No abstract available.

5

Immunosuppressive therapy of lupus nephritis.

Dooley MA, Falk RJ. Dooley MA, et al. Lupus. 1998;7(9):630-4. doi: 10.1191/096120398678920767. Lupus. 1998. PMID: 9884101 Review.

6

Mycophenolate mofetil therapy in lupus nephritis: clinical observations.

Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA. Dooley MA, et al. J Am Soc Nephrol. 1999 Apr;10(4):833-9. J Am Soc Nephrol. 1999. PMID: 10203368 Clinical Trial.

7

A multidisciplinary renal clinic for corticosteroid-induced bone disease.

Joy MS, Neyhart CD, Dooley MA. Joy MS, et al. Among authors: dooley ma. Pharmacotherapy. 2000 Feb;20(2):206-16. doi: 10.1592/phco.20.3.206.34787. Pharmacotherapy. 2000. PMID: 10678299 Clinical Trial.

8

Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis.

Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ; Glomerular Disease Collaborative Network. Hogan SL, et al. Among authors: dooley ma. J Am Soc Nephrol. 2001 Jan;12(1):134-42. J Am Soc Nephrol. 2001. PMID: 11134259

9

Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Cooper GS, et al. Among authors: dooley ma. J Rheumatol. 2001 Dec;28(12):2653-6. J Rheumatol. 2001. PMID: 11764212

10

Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Cooper GS, et al. Among authors: dooley ma. Arthritis Rheum. 2002 Jul;46(7):1830-9. doi: 10.1002/art.10365. Arthritis Rheum. 2002. PMID: 12124867

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results